- 1 Viral cultures, Polymerase Chain Reaction Cycle Threshold Values and
- **2 Viral Load Estimation for SARS-CoV-2 Infectious Potential Assessment**
- 3 in Hematopoietic Stem Cell and Solid Organ Transplant Patients: A
- 4 Systematic Review.
- 5 Tom Jefferson¹, Elizabeth A. Spencer², John M. Conly⁷, Elena C. Rosca³, Susanna Maltoni⁴, Jon
- 6 Brassey⁵, Igho J. Onakpoya¹, David H. Evans⁶, Carl J. Heneghan², Annette Plüddemann^{2*}.
- ¹Department for Continuing Education, University of Oxford, UK
- 8 ²Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences,
- 9 University of Oxford, UK
- 10 ³Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
- ⁴Division of Research and Innovation, IRCCS Azienda Ospedaliero-Universitaria di Bologna,
- 12 Bologna, Italy
- 13 ⁵Trip Database Ltd, Newport, UK
- 14 ⁶Li Ka Shing Institute of Virology and Dept. of Medical Microbiology & Immunology, University
- 15 of Alberta, Canada
- ⁷Departments of Medicine, Microbiology, Immunology & Infectious Diseases, and Pathology &
- 17 Laboratory Medicine, Synder Institute for Chronic Diseases and O'Brien Institute for Public

- Health, Cumming School of Medicine, University of Calgary and Alberta Health Services,
- 19 Calgary, Canada.

22

20 *Corresponding author

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

Abstract Background: Organ transplant recipients are at increased vulnerability to SARS-CoV-2 due to immunosuppression and may pose a continued transmission risk especially within hospital settings. Detailed case reports including symptoms, viral load and infectiousness, defined by the presence of replication-competent viruses in culture, provide an opportunity to examine the relationship between clinical course, burden and contagiousness, and provide guidance on release from isolation. Objectives: We performed a systematic review to investigate the relationship in transplant recipients between serial SARS-CoV-2 RT-PCR cycle threshold (Ct) value or cycle of quantification value (Cq), or other measures of viral burden and the likelihood and duration of the presence of infectious virus based on viral culture including the influence of age, sex, underlying pathologies, degree of immunosuppression, and/or vaccination on this relationship. Methods: We searched LitCovid, medRxiv, Google Scholar and WHO Covid-19 databases, from 1 November 2019 until 31 December 2021. We included studies reporting relevant data for transplantees with SARS-CoV-2 infection: results from serial RT-PCR testing and viral culture data from the same respiratory samples. We assessed methodological quality using five criteria, and synthesised the data narratively and graphically. Results: We included 10 case reports and case series reporting on 38 transplantees. We observed a relationship between proxies of viral burden and likelihood of shedding replicationcompetent SARS-CoV-2. Two individuals shed replication-competent viruses over 100 days after

infection onset. Lack of standardisation of testing and reporting platforms precludes

establishing a definitive viral burden cut-off. However, most transplantees stopped shedding competent viruses when the RT-PCR cycle threshold was above 30 despite differences across platforms. Conclusions Viral burden is a reasonable proxy for infectivity when considered within the context of the clinical status of each patient. Standardised study design and reporting are essential to standardise guidance based on an increasing evidence base. **Keywords** COVID-19; SARS-CoV-2; transmission; organ transplants; viral culture; polymerase chain reaction; viral load; cycle threshold calibration; infectivity

Introduction

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

77

Hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients have significant immunosuppression, affecting both cellular and humoral immunity, and less favourable outcomes with Severe Acute Respiratory Virus Syndrome 2 (SARS-CoV-2) infection, due to the immunosuppression and/or to pre-existing comorbidities¹. Immunosuppression associated with transplantation places patients at risk for prolonged carriage and shedding of several respiratory viruses². However, identification of respiratory viral shedding, recently by reverse transcriptase polymerase chain reaction (RT-PCR), depending on the testing platform does not correlate with the presence of replication-competent virus³. Accordingly, we sought to perform a systematic review of RT-PCR testing and viral culture of SARS-CoV-2, focussing on people receiving solid organ or hematopoietic stem cell transplants, following our published protocol⁴.

Our research questions were:

- 1. What is the correlation between serial SARS-CoV-2 RT-PCR cycle threshold (Ct) value or cycle of quantification value (Cq), or other measures of viral burden and the likelihood of producing replication-competent virus?
- 76 2. What is the likelihood and duration of the presence of infectious virus based on viral culture, among transplant recipients with SARS-CoV-2 infection?
- 78 3. What is the influence of age, sex, underlying pathologies and degree of 79 immunosuppression on infectiousness of SARS-CoV-2?

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

4. What is the relationship of vaccination status on infectiousness with SARS-CoV-2? We included studies reporting serial Cts from sequential RT-PCR testing or other measures of viral burden such as RNA gene copies of respiratory samples (from nasopharyngeal or throat specimens) along with viral culture data on the same samples, from patients about to receive a transplant or who were post-transplant, with SARS-CoV-2 infection. Methods **Search Strategy** We searched the following electronic databases: LitCovid, medRxiv, Google Scholar and the WHO Covid-19 database from November 2019 until December 31, 2021. No language restrictions were applied. The literature search terms were: (coronavirus OR covid-19 OR SARS-CoV-2) AND (immunosuppressed OR immunocompromised OR transplant OR immunosuppression OR "immune deficient" OR HIV) AND (CPE OR "cytopathic effect" OR "Viral culture" OR "virus culture" OR vero OR "virus replication" OR "viral replication" OR "cell culture" or "viral load" OR "viral threshold" OR "log copies" OR "cycle threshold"). Screening Four reviewers independently screened titles and abstracts to identify studies for consideration of full text. Full text screening was performed in duplicate and disagreements arbitrated by a fifth reviewer.

Inclusion criteria

We included studies reporting serial Cts from sequential RT-PCR testing, or RNA gene copies of respiratory samples (nasopharyngeal, throat, sputum, bronchoalveolar lavage, endotracheal tube secretions) AND viral culture data from the same samples from patients about to receive a transplant or post-transplant with SARS-CoV-2 infection. We included primary studies provided they reported sufficient information to extract quantitative data on the PCR testing and the viral culture for each included individual. Studies that included transplant and non-transplant patients were included if we could ascertain the results separately. Studies reported only in poster or abstract form were excluded. Reviews were excluded but the reference lists screened for potential relevant primary studies.

Exclusion criteria

We excluded studies using post-mortem samples only and non-respiratory samples only. We did not include studies of non-transplant patients or those not attempting viral cultures.

Data extraction

One reviewer extracted data, which was independently checked by a second reviewer. Disagreements were arbitrated by a third reviewer. Data were extracted on study type and study characteristics, including population, setting, sampling and laboratory methods, clinical information, prescribed treatments, vaccination status, laboratory findings, and clinical outcomes. For three studies we sought clarification from the corresponding authors.

Quality assessment

131

119 We assessed the quality of included studies according to five criteria: 120 1. Were the criteria for diagnosing a case clearly reported and appropriate? 2. Was the reporting of patient/population characteristics including clinical symptoms, 122 treatments with degree of immunosuppression and outcomes adequate? 123 3. Was the study period, including follow-up, sufficient to adequately assess any potential 124 relationship between viral burden measures and likelihood of producing replication-125 competent virus and the rise in neutralising antibodies? We defined sufficient as more 126 than one observation. 127 4. Were the methods used to obtain RT-PCR results replicable, generalisable and 128 appropriate? We considered that each study should establish the relationship between 129 their Ct values and the target gene copy number, using internal standards. 130 5. Were the methods used to obtain viral culture results replicable and appropriate? We considered the methods used should, at a minimum, include a description of specimen 132 sampling and management, preparation, media and cell line used, exclusion of 133 contamination or co-infection (use of good controls and appropriate antibacterials and 134 antimycotics and possible use of gene sequencing if available), and results of inspection 135 of culture. 136 Data reporting and pooling 137 We reported study flow according to PRISMA reporting standards⁵. We reported study 138 characteristics including age, sex, clinical symptoms, treatments and events in the participants

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

in tabular form. We presented data on disease burden measures and on viral culture in tabular form. For studies reporting more than one patient participant, data were extracted related to each participant if available. We plotted median, interquartile ranges (IQRs) and outliers for viral culture results in relation to the duration of symptoms, and individual study plots to day 120 of viral culture results and cycle thresholds. We were unable to meta-analyse the data on PCR cycle counts/RNA log copies and viral culture, due to a lack of detailed information on laboratory practices, assays and because of the absence of internal controls in some studies, and heterogeneous sampling. We therefore reviewed the studies narratively, and where possible presented the results graphically within the limitations noted. We analysed the relationship between cycle threshold, days of onset of symptoms and likelihood of shedding replication-competent virus by presenting the data on a scatter plot **Results** The literature search identified 12,988 titles for screening. Of these 63 underwent full-text review. A total of 53 studies were excluded after full-text analysis: reasons are reported in the list of excluded studies (see Supplementary File: List of excluded studies) The 10 included studies (Figure 1 reported data for 30 transplant patients (7 females and 23 males): renal (21), cardiac (5), bone marrow transplant (9), liver (2), bilateral lung (1). For one study the number of males and females was not available for the relevant patient group . ⁶ The 38 patients were in seven countries: Saudi Arabia⁷, France ^{8 9}, Germany ^{10 11 12}, Austria ¹³,

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

Denmark ¹⁴, Canada ¹⁵ and the USA⁶, and were aged between 26 and 77 years old. A total of 36 were infected with SARS-CoV-2 post-transplant: 21 patients in 3 studies had had kidney transplant ^{7 8 12}, 5 patients in 4 studies had had a cardiac transplant ^{7 10 15 9}, 1 previous bone marrow transplant for multiple myeloma ¹⁴, 1 liver transplant ¹⁴ and eight hematopoietic cell transplants⁶. Two patients were infected with SARS-CoV-2 and subsequently underwent transplant: 1 liver transplant ¹¹, 1 patient had bilateral lung transplantation after a SARS-CoV-2 infection that severely affected the lungs ¹³. Typically, patients received ⁶a mixture of antivirals, antibiotics, convalescent plasma and immune suppressants, as reported in Table 1. The clinical course of COVID-19 varied widely amongst the included patients, from mild COVID-19 related symptoms to severe pneumonia and lung failure; no deaths were specifically reported for this group, although deaths were reported for 4 aggregate patients in one study within 30 days of diagnosis⁶. Prescribed treatments reflected the variation in severity. **Quality Assessment** Table 2 reports study quality based on five criteria. Three studies ^{15 9 12} met all five criteria. Follow-up was judged adequate in all studies; in nine studies the reporting of patient characteristics was sufficiently comprehensive^{6 8 10 13 11 14 15 9 12} and clinical information was missing for one study 7. Case definition was missing or unclear in four studies 6, 7 10 14, and methods for RT- PCR testing were unclear for three studies⁶ ¹⁰ ¹³. The methods used for viral culture were unclear in four studies ^{7 10 13 11} and one study reported using a cell line that has not typically been used to demonstrate SARS-CoV-2 growth - Buffalo green monkey kidney

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

(BGMK) cell line8. Results of the studies The results are reported in Table 1 and Table 3. The clinical course of infection was highly variable (Tables and 1 and 3, and Figures 2 and 3). The time from transplant to infection varied from days to years (see for example Aydillo et al⁶ and Rajakumar et al¹⁵). Sampling schedules varied between studies, with no regular timetable of testing taking place, so results for PCR and viral culture are available for different time points in a patient's clinical course and with different gaps in time between samples being taken. In response to our first study question on the correlation between proxy indicators of viral burden and infectiousness, the data from Figures 2 and 3 and Table 3 indicate a correlation between viral burden (measured as log copies or Cq/Ct) and probable infectiousness. The data suggests that earlier symptom onset is related to the likelihood of shedding replicationcompetent virus (Figure 2). The median time for a positive culture from onset of symptoms was 16 days (IQR 8 to 27; range 1-105, mean 19.7 days n = 59 cultures performed). The median for a negative culture was 40 days, mean 40.2 days (IQR 22 to 60; range 1-119, n = 107 cultures performed). Five patients reported by Alshukairi et al were all culture-negative; this was in samples taken on days 9,12, 17,18 and day 26 since symptom onset, respectively 7. Seven stem cell transplant recipients from the Aydillo et al letter who had repeated culture

assessments fluctuated in and out of shedding replication-competent virus. One who had a

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

single culture attempt was positive with an estimated Ct of 17.5 6. Patient MSK-6 shed replication competent virus until day 62 from symptom onset with an estimated Ct of 19. MSK-6 showed the longest duration infectious transplant recipient from the Aydillo et al letter⁶. Eight kidney transplant patients described by Benotmane and colleagues had positive viral cultures 8. For six patients we could identify the duration of probable infectiousness, which ranged from 8 days (patient 5: day 1 to 8) to 32 days (patient 7: day 7 to 38). Four patients were infectious with reported Cts> 30 based on the individual platforms that were used to perform the Cts. Rajakumar et al¹⁵ described two cardiac transplant patients: viral culture found replicationcompetent virus in samples from one patient on day 16 and in samples from the other patient on day 4 and repeatedly up to day 27, after which all viral cultures were negative 15. For each patient, viral culture was negative (i.e. no replication-competent virus observed) in samples with PCR cycle counts of over 25. Within the samples giving positive viral cultures, the PCR results showed that the cycle threshold for the N gene was lower than for the E gene by an average of 5.4 Ct values. In the study by Niyonkuru et al, the duration of infectiousness in the two patients, as indicated by replication-competent virus, was 8 and 9 days (Figure 3) 14. A cardiac transplant patient described by Tarhini⁹ and colleagues tested culture-positive with a Ct of 23 on day 103; all other viral cultures were negative from samples with PCR Cts of 18 to over 40 9. Weigang et al¹² described a kidney transplant patient who experienced three hospital

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

admissions. During the first one (day zero to day 72), 19 RT-qPCR tests were performed, and alongside that viral culture was performed, showing 8/19 positive cultures (Ct values ranging from 15 to 25) and 11/19 negative (Ct values from 25 to 30). The patient was culture positive again on day 105 (Ct of 23). After re-admission at day 140 the patient was still RT-qPCR positive, but with viral culture negative; he was treated for 10 days (days 141-149) with remdesivir. Subsequently, negative RT-qPCR tests until day 189 and negative cultures suggested that the infection had resolved¹². A heart transplant patient described by Decker¹⁰ and co-workers had a positive viral culture on day 18 and day 21 with 6.2 and 6.5 log10 copies/ml. 10 Although the dataset was limited, we observed an inverse relationship (Ct/Cq) or direct relationship (log copies): the viral burden indicated by these methods correlated with infectiousness, as shown by the ability to produce replication-competent virus in culture. The presence of replication-competent virus reflects one of the highest grades of evidence supporting the capability for forward transmission of SARS-CoV-2^{16, 17}. The robustness of the correlation is difficult to assess because laboratory methods differ; it was not possible to pool the data to produce a summary cut-off value for infectiousness, due to these variations and due to varying time windows for sampling from patients (see Figure 2 and Table 3). In response to our second research question (on the likelihood and duration of infectiousness among transplant recipients with SARS-CoV-2 infection) the data indicate that regardless of differences in laboratory practices, observed prolonged shedding of replication-competent

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

virus is associated with alternating increases and decreases of viral burden over time, which in some cases may be up to around 100 days 9 12. Figure 4 shows the relationship between cycle threshold, symptom onset (in days) and likelihood of shedding replication competent virus. In Benotmane, five results were reported with a CT of 30 or above for a positive culture. [8] However, the cell line used in this study is not demonstrated to support SARS-CoV-2 growth. In the other studies, despite a minimum of 10 different PCR platforms being used and different culture techniques, the culture results are insensitive to cycle thresholds above 30. The viral load estimates are affected by administration of courses of anti-viral treatment including remdesivir. See Figures 3a (Cts/Cqs) and 3b (log copies). Responding to our third research question (the influence of age, sex, underlying pathologies and degree of immunosuppression on infectiousness): at present the heterogeneity and limited amount of the available data preclude answering this question. We are unable to answer our fourth and final research question on the relationship of vaccination status on infectiousness because no study reported on vaccination status for these transplant patients.

Discussion

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

This review included 10 reports of studies using viral culture and RT-qPCR testing among 38 transplant patients with immunosuppressive treatment who experienced COVID-19 infection. The evidence indicates a relationship between indicators of viral burden (Ct, Cg or RNA log copies) and probable infectiousness as indicated by the presence of replication-competent virus. Gaps in the data remain due to variable methods and reporting and establishing summary estimates of the relationship has not been possible. The data show a long-term rise and fall of viral burden associated with the likelihood of infectiousness that in some transplant patients appears to be a sequential pattern of going in and out of infectiousness. Replication-competent virus was most commonly observed in samples with PCR Ct values under 25; one study was an exception to this by reporting viable virus at Ct>30, but the use of a cell line not typically used for SARS-CoV-2 isolation makes interpretation unclear⁸. The duration of viral RNA shedding was variable, with the longest duration reported at 105 days¹². Our findings suggest a Ct of 30 or greater, regardless of the platform, may be used as a reasonable proxy to rule out infectious SARS-CoV-2 as there is a consistent correlation between a rising Ct value and likelihood of isolating replication-competent virus. Such a value would be useful to guide clinicians managing these difficult patients, particularly if there were repeated values in this range. Below a Ct of 30, clinicians may choose to repeat NP or throat swabs to assess the direction of the Ct values to allow a more dynamic assessment which taken in conjunction with the clinical status may faciltate decision making for isolation or antiviral treatment considerations.

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

Regarding our third review question on the influence of patient variables on the likelihood of the presence of infectious SARS-CoV-2, the included studies showed substantial heterogeneity; some had missing data or few cultures available, and meta-analysis or pooling was not possible. Variability in the clinical course of SARS-CoV-2 infection among transplant recipients has been reported, including observed prolonged viral shedding¹⁸. Antiviral drugs may impact on these observations, especially symptoms and viral burden. ¹⁹ Two well-designed studies on immunosuppressed patients, which we were unable to include because disaggregated data solely for transplant patients were not fully available, support our conclusions^{6, 20}. While this review is limited to transplant patients, evidence suggests similar prolonged viral cultures are found in immunosuppressed cancer patients. We plan to perform a further review in this group analysing the type of cancer and the impact of immunotherapies on viral culture findings. The transplant patient population is of particular importance: clinicians need guidance as to when to release the patient from quarantine or isolation, given the heavy burden of immunosuppression. We have tried to narrow the uncertainty and offer some general guidance as to when patients are unlikely to be shedding replication-competent virus, but clinical assessment of each patient must inform that decision because each patient and setting is different. The strengths of this review are that we followed our published protocol, entailing rigorous literature searches, double checked data extraction and quality assessment, and a high level of clinical and epidemiological expertise input to deliberate the findings. We were also able to

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

include data from an additional 8 transplant recipients after extensive correspondence with the study authors⁶. Limitations include the small number of studies with viral culture and serial viral load estimates among transplant patients, high variability in study design and reporting and impossibility to pool results due to the well-known variability in sensitivity across assays²¹. Case series are conventionally considered low in the evidence hierarchy, as they may entail inherent bias in the selection of study participants and therefore have limited generalisability; however, here they are essential in providing the detailed reports needed for this unusual patient group. The case reports included here comprise some of the most detailed longitudinal reports of this patient group for whom data are needed. The evidence base is limited, however, by heterogeneous design and reporting within the studies with, for example, different observation windows for reporting of viral burden and culturability or clinical characteristics of patients. In addition to providing appropriate care for the individual patient, ongoing transmission of SARS-CoV-2 is a concern, and immunosuppressed individuals may pose a challenge by experiencing prolonged carriage of the virus that could lead to forward transmission. Based on our findings we would offer the following general guidance to clinicians: Physicians who are experienced with these immunosuppressed patient populations should work with public health to direct their isolation and quarantine requirements. Infectious patients with immunosuppressive treatment following solid organ or stem cell transplantation should be isolated until at least two consecutive respiratory specimens collected ≥24 hours apart demonstrate a rising RT-PCR Ct (i.e. indicating diminishing viral burden). After discharge,

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

they should be closely followed up for SARS-CoV-2 infection for several weeks to months, depending on the individual clinical scenario. For obtaining data, standardisation of methods is needed: each laboratory should use consistently applied platforms with suitable internal standards to calibrate the relationship between Ct and genome copy in these patient populations. Publication of results of case series or other longitudinal study should be reported in a standardised format to avoid loss of data. We suggest observation windows should be within a short range of 3 to 7 days during the acute periods post-transplantation and during periods of rejection when higher doses of immunosuppressants are employed, depending on clinical circumstances. Each observation window should include a summary of symptoms and interventions, the reporting of PCR cycle threshold and, for samples with Ct below 30, attempts at viral culture if available. Description of patients should include past medical histories and details of treatments received. Observed drug interactions should be highlighted. Reasons for admission, discharge and changes in isolation should be clearly reported. To investigate the duration of viral shedding, studies should report the time between the first positive and the first negative viral cultures. With additional data gathering and standardisation of methods, it will be possible for transplant physicians to develop evidence-based approaches to dealing with these patients for the benefit of the patients and their families and the community at large.

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

Acknowledgements We gratefully acknowledge the contributions of Drs Mini Kamboj and Jeroen van Kampen who provided additional data from their studies and helped us to progress this work. **Funding** This work is supported by the National Institute for Health Research School for Primary Care Research [Project 569] and by the University of Calgary. **Author contributions** TJ, CH and JC designed the study. JB performed the literature searches. JB, TJ, SM, ER and ES, screened the studies for eligibility and performed data extraction. Additional expertise on clinical and laboratory issues was given by DE, JC, SM and ER. CH generated the data figures. All authors contributed to interpreting and writing up the results and conclusions. **Ethics declarations** Ethics approval and consent to participate: This is a systematic review and meta-analysis. Therefore, ethical approval is not applicable. Consent for publication:

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

Not applicable. Availability of data and materials All data generated or analysed during this study are included in this published article [and its supplementary information files]. **Competing Interests** TJ's competing interests are accessible at: https://restoringtrials.org/competing-interests-tomiefferson CJH holds grant funding from the NIHR, the NIHR School of Primary Care Research, the NIHR BRC Oxford and the World Health Organization for a series of Living rapid review on the modes of transmission of SARs-CoV-2 reference WHO registration No2020/1077093. He has received financial remuneration from an asbestos case and given legal advice on mesh and hormone pregnancy tests cases. He has received expenses and fees for his media work including occasional payments from BBC Radio 4 Inside Health and The Spectator. He receives expenses for teaching EBM and is also paid for his GP work in NHS out of hours (contract Oxford Health NHS Foundation Trust). He has also received income from the publication of a series of toolkit books and for appraising treatment recommendations in non-NHS settings. He is Director of CEBM and is an NIHR Senior Investigator.

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

DE holds grant funding from the Canadian Institutes for Health Research and Li Ka Shing Institute of Virology relating to the development of Covid-19 vaccines as well as the Canadian Natural Science and Engineering Research Council concerning Covid-19 aerosol transmission. He is a recipient of World Health Organization and Province of Alberta funding which supports the provision of BSL3-based SARS-CoV-2 culture services to regional investigators. He also holds public and private sector contract funding relating to the development of poxvirus-based Covid-19 vaccines, SARS-CoV-2-inactivation technologies, and serum neutralization testing. JMC holds grants from the Canadian Institutes for Health Research on acute and primary care preparedness for COVID-19 in Alberta, Canada and was the primary local Investigator for a Staphylococcus aureus vaccine study funded by Pfizer for which all funding was provided only to the University of Calgary. He is co-investigator on a WHO funded study using integrated human factors and ethnography approaches to identify and scale innovative IPC guidance implementation supports in primary care with a focus on low-resource settings and using drone aerial systems to deliver medical supplies and PPE to remote First Nations communities during the COVID-19 pandemic. He also received support from the Centers for Disease Control and Prevention (CDC) to attend an Infection Control Think Tank Meeting. He is a member and Chair of the WHO Infection Prevention and Control Research and Development Expert Group for COVID-19 and a member of the WHO Health Emergencies Programme (WHE) Ad-hoc COVID-19 IPC Guidance Development Group, both of which provide multidisciplinary advice to the WHO and for which no funding is received and from which no funding recommendations are made for any WHO contracts or grants. He is also a member of the Cochrane Acute Respiratory Infections Working Group.

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

JB is a major shareholder in the Trip Database search engine (www.tripdatabase.com) as well as being an employee. In relation to this work Trip has worked with a large number of organisations over the years, none have any links with this work. The main current projects are with AXA and SARS-CoV-2 (WHO Registration 2020/1077093-0) and is part of the review group carrying out rapid reviews for Collateral Global. He worked on Living rapid literature review on the modes of transmission of SARS-CoV-2 and a scoping review of systematic reviews and metaanalyses of interventions designed to improve vaccination uptake (WHO Registration 2021/1138353-0). ECR was a member of the European Federation of Neurological Societies (EFNS) / European Academy of Neurology (EAN) Scientist Panel, Subcommittee of Infectious Diseases (2013 to 2017). Since 2021, she is a member of the International Parkinson and Movement Disorder Society (MDS) Multiple System Atrophy Study Group, the Mild Cognitive Impairment in Parkinson Disease Study Group, and the Infection Related Movement Disorders Study Group. She was an External Expert and sometimes Rapporteur for COST proposals (2013, 2016, 2017, 2018, 2019) for Neurology projects. She is a Scientific Officer for the Romanian National Council for Scientific Research. AP holds grants from the NIHR School for Primary Care Research. IJO and EAS have no interests to disclose. SM is a pharmacist working for the Italian National Health System since 2002 and a member of one of the three Institutional Review Boards of Emilia-Romagna Region (Comitato Etico Area Vasta Emilia Centro) since 2018.

References

422

423

- 424 1. Jering, K.S., et al., Excess mortality in solid organ transplant recipients hospitalized with COVID-425 19: A large-scale comparison of SOT recipients hospitalized with or without COVID-19. Clin 426 Transplant, 2022. **36**(1): p. e14492. 10.1111/ctr.14492.
- 427 2. Andersen, K.M., et al., Long-term use of immunosuppressive medicines and in-hospital COVID-19 428 outcomes: a retrospective cohort study using data from the National COVID Cohort 429 Collaborative. (2665-9913 (Electronic)).
- 430 3. Fernández-Ruiz, M. and J.M. Aguado, *Severe acute respiratory syndrome coronavirus 2 infection*431 *in the stem cell transplant recipient clinical spectrum and outcome.* Curr Opin Infect Dis, 2021.
 432 **34**(6): p. 654-662. 10.1097/qco.00000000000790.
- 433 4. Jefferson, T., et al., Viral cultures, PCR Cycle threshold values and viral load estimation for
 434 COVID-19 infectious potential assessment in transplant patients: systematic review Protocol
 435 Version 30 December 2021. medRxiv, 2022: p. 2021.12.30.21268509.
 436 10.1101/2021.12.30.21268509.
- 437 5. Page, M.J., et al., *The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.* BMJ, 2021. **372**: p. n71. 10.1136/bmj.n71.
- 439 6. Aydillo, T., et al., *Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer.*440 New England Journal of Medicine, 2020. **383**(26): p. 2586-2588. 10.1056/NEJMc2031670.
- 441 7. Alshukairi, A.N., et al., *Test-based de-isolation in COVID-19 immunocompromised patients: Cycle*442 *threshold value versus SARS-CoV-2 viral culture*. International Journal of Infectious Diseases,
 443 2021. **108**: p. 112-115. 10.1016/j.ijid.2021.05.027.
- 8. Benotmane, I., et al., *Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients*with COVID-19. American Journal of Transplantation, 2021. **21**(8): p. 2871-2875.
 https://doi.org/10.1111/ajt.16636.
- 447 9. Tarhini, H., et al., Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
 448 Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to
 449 SARS-CoV-2 Superinfection. The Journal of Infectious Diseases, 2021. 223(9): p. 1522-1527.
 450 10.1093/infdis/jiab075.
- 451 10. Decker, A., et al., *Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after* 452 recent heart transplantation. Am J Transplant, 2020. **20**(11): p. 3239-3245. 10.1111/ajt.16133.
- Niess, H., et al., Liver transplantation in a patient after COVID-19 Rapid loss of antibodies and prolonged viral RNA shedding. Am J Transplant, 2021. **21**(4): p. 1629-1632. 10.1111/ajt.16349.
- 455 12. Weigang, S., et al., *Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19*456 patient: a source of immune escape variants. medRxiv, 2021: p. 2021.04.30.21256244.
 457 10.1101/2021.04.30.21256244.
- 458 13. Lang, C., et al., Lung transplantation for COVID-19-associated acute respiratory distress
 459 syndrome in a PCR-positive patient. The Lancet Respiratory Medicine, 2020. **8**(10): p. 1057-1060.
 460 10.1016/S2213-2600(20)30361-1.
- 461 14. Niyonkuru, M., et al., *Prolonged viral shedding of SARS-CoV-2 in two immunocompromised*462 *patients, a case report.* BMC Infectious Diseases, 2021. **21**(1): p. 743. 10.1186/s12879-021463 06429-5.
- 464 15. Rajakumar, I.A.-O., et al., Extensive environmental contamination and prolonged severe acute respiratory coronavirus-2 (SARS CoV-2) viability in immunosuppressed recent heart transplant recipients with clinical and virologic benefit with remdesivir. (1559-6834 (Electronic)).

- 467 16. Jefferson, T., et al., *Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) from pre and asymptomatic infected individuals. A systematic review.* Clinical Microbiology and Infection, 2021. https://doi.org/10.1016/j.cmi.2021.10.015.
- 470 17. Jefferson, T.H., C.; Spencer, E.; Brassey, J.; Pluddeman, A.; Onakpoya, I.; Evans, D.; Conly, J. A
 471 *Hierarchical Framework for Assessing Transmission Causality of Respiratory Viruses.* PrePrints,
 472 2021. 10.20944/preprints202104.0633.v1.
- 473 18. Marinelli, T., et al., *Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant Recipients.* Transplantation, 2021. **105**(10): p. 2175-2183. 10.1097/tp.000000000003860.
- Thornton, C.S., et al., *Prolonged SARS-CoV-2 infection following rituximab treatment: clinical*course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values. Antimicrob Resist Infect Control, 2022. **11**(1): p. 28. 10.1186/s13756-022-01067-1.
- van Kampen, J.J.A., et al., Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants. medRxiv, 2020: p.
 2020.06.08.20125310. 10.1101/2020.06.08.20125310.
- 483 21. Bruce, E.A., et al., *Predicting infectivity: comparing four PCR-based assays to detect culturable SARS-CoV-2 in clinical samples.* EMBO Mol Med, 2021: p. e15290. 10.15252/emmm.202115290.

486

List of tables and figures.

- Table 1. Characteristics of transplant patients in included studies.
- Table 2. Quality of included studies.
- Table 3. PCR cycle counts/log copies and viral culture results of included studies.
- Figure 1. PRISMA flow chart of study screening for inclusion.
- Figure 2. SARs-CoV-2 culture results in transplant patients from days of symptom onset.
- Figure 3. Duration of infectivity as indicated by viral culture and corresponding PCR cycle counts/log copies among transplant recipients.
- Figure 4. Relationship between cycle threshold and symptom onset (in days)

List of supplementary files.

Supplementary file. Literature search strategy.

Supplementary file. List of excluded studies, with reasons.

Table 1. Characteristics of transplant patients in included studies.

Study ID	Participants	Transplant,	Clinical course	COVID-19
	(data extracted	immunosuppressive	of COVID-19	treatments
	for transplant	treatment &	infection	
	patients)	comorbidities		
Alshukairi 2021	Pt1: 34 yr F	Pt1: cardiac, in 2014,	Pt1: Severe	Pt1: high-flow
	Pt2: 71 yr M	tacrolimus, MMF,	pneumonia;	nasal cannula
	Pt3: 75 yr M	prednisolone	Pt2:	Pt2: low-flow
	Pt4: 26 yr M	Pt2: renal, in 2014,	pneumonia	cannula

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
	Pt5: 38 yr F	tacrolimus, MMF, prednisolone, DM, HTN, CAD Pt3: renal, in 2014, tacrolimus, MMF and prednisolone, HTN Pt4: renal, in 2018, tacrolimus, MMF, prednisolone, DM Pt5: renal in 2014, tacrolimus, AZA, prednisolone, APS & hypothyroidism.	Pt3: pneumonia Pt4: pneumonia Pt5: upper RTI	Pt3: low-flow cannula Pt4: oxygen not required Pt5: no cannula
Aydillo 2020	8 ppts (no. of M and F and age N/A for this	Various antibiotics and immunosuppressants	Variable from mild to severe	Hydroxychloroq uine, remdesivir,

Study ID	Participants (data extracted	Transplant, immunosuppressive	Clinical course of COVID-19	COVID-19 treatments
	for transplant patients)	treatment & comorbidities	infection	
	subset)			azythromicin, convalescent plasma
Benotmane I 2021	14 M, 2 F, median age 63.3 yrs. Pts with at least two positive for SARS-CoV-2 NP swabs (of which one collected at least 7 days after symptom onset) during the follow-up	16 kidney transplant recipients; median time from transplant 3.8 yrs. Antithymocite globulin: 8/16; anti-CD25: 8/16; tacrolimus: 10/16; ciclosporin: 3/16; MMF/MPA: 14/16; mTOR inhibitors:	All 16 hospitalized for symptomatic COVID-19 between 4 March and 15 April 2020	lopinavir/ ritonavir: 1/16; hydroxychloroq uine: 8/16; tocilizumab: 2/16
	period were	2/16; steroids: 10/16;		

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
	eligible for inclusion	belatacept: 2/16		
Decker A 2020	62 yr M	Heart transplant Nov 2019; subsequently pneumonia and acute respiratory distress syndrome; intermittent renal replacement therapy. Cyclosporine A (target range 135 ± 30 ng/mL), mycophenolate mofetil 500 mg b.i.d., prednisone 10 mg q.d.	1 March 2020 onset of symptoms and +ve PCR; mild symptoms, no cardiorespirato ry decline, several weeks +ve.	hydroxychloroq uine (400mg b.i.d. + 200mg b.i.d.) from day 7 to 14

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
		+ cotrimoxazole and due to cytomegalovirus highrisk constellation (D + R-), ganciclovir for 4 months posttransplantation, then valganciclovir prophylaxis.		
Lang C 2020	44 yr old F with mild untreated psoriatic arthritis and idiopathic CD4 lymphocytopen	Bilateral lung transplant day 58 after admission for Covid-19. Subsequently, standard triple	Day 0 admitted with fever, cough, +ve NP RT-PCR. Day 6 to ICU & intubation; day	Immunoglobuli ns, tocilizumab & lopinavir. Day 6 to ICU & intubation; day

Study ID	Participants (data extracted	Transplant,	Clinical course of COVID-19	COVID-19 treatments
	for transplant	treatment &	infection	
	patients)	comorbidities		
	ia	immunosuppression	13 ECMO. Day	13 ECMO.
		was initiated,	52 preparation	Bilateral lung
		including tacrolimus,	begun for	transplant
		mycophenolate	transplant:	
		mofetil, and steroids;	immunoabsorp	
		also 6 additional	tion therapy;	
		treatment cycles of	day 58 bilateral	
		immunoabsorption	lung transplant	
		and antithymocyte	performed.	
		globulin.	Transferred to	
			non ICU ward	
			day 121.	
Niess 2020	56 yr M patient	admission for liver		
	listed for liver	transplant: 18/3/2020		
	transplantation	positive to COVID-19		
	with a Model	screening on		

Study ID	Participants	Transplant,	Clinical course	COVID-19
	(data extracted	immunosuppressive	of COVID-19	treatments
	for transplant	treatment &	infection	
	patients)	comorbidities		
	For End-Stage	25/3/2021		
	Liver Disease	after 31-32 days: PCR		
	Score of 19	negative +		
	points due to	seroconversion		
	cryptogenic	after 36 days of		
	cirrhosis and a	symptom onset and		
	history of	21 days after		
	hepatitis B	seronconversion:		
		transplant; tacrolimus		
		(to target of 4 to 7		
		ng/ml) + steroids		
Niyonkuru M	Pt1: 66 yr M,	Pt1: fatigue and	Pt1 day 0 +ve	Pt1: In ICU, non
2021	recent liver	tachypnea, hospital	test. Symptom	invasive
	transplant	admission, tested	onset day 5,	ventilation, IV
		positive for SARS-CoV-	diminished	dexamethason
	Pt2: 70 yr M,	2	taste and	e 6 mg daily

Study ID	Participants	Transplant,	Clinical course	COVID-19
	(data extracted for transplant	immunosuppressive treatment &	of COVID-19 infection	treatments
	patients)	comorbidities		
	previous bone		smell; day 12	and remdesivir:
	marrow	Pt2: pacemaker.	additional	200 mg the first
	transplant for	Lenalidomide	symptoms; day	day and 100 mg
	multiple	25 mg daily. elevated	14 hospital	the following 4
	myeloma	CRP concentration	admission. On	days.
		(130 mg/L).	day 12 from	
		Nocardia Farcinica	symptom	Pt2: no COVID-
		was detected in blood	onset	19 treatment
		cultures and	transferred to	(asymptomatic)
		pus from abscesses	the ICU for non	
		on the left leg. Trans-	invasive	
		esophageal	ventilation.	
		echocardiography		
		showed vegetation on	Pt2 admitted	
		the pacemaker	on October 21	
		electrode.	due to fever	
			and elevated	

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
			concentration (130 mg/L) because of systemic infection due to pacemaker contamination; periodic screening during admission; positive by week 4, always asymptomatic of COVID-19.	

Study ID	Participants	Transplant,	Clinical course	COVID-19
	(data extracted	immunosuppressive	of COVID-19	treatments
	for transplant	treatment &	infection	
	patients)	comorbidities		
Rajakumar 2021	Two cardiac	Pt1: orthotopic heart	NP swabs (&	Pt1: after day
	transplant	transplant with	saliva & clinical	15,
	recipients (<3	antithymocyte	&	corticosteroids
	months post-	globulin induction &	environmental	&
	transplant):	standard triple	samples) were	antimicrobials
	Pt1: 56 yr F;	immunosuppressive	collected at	initiated for
	history of	therapy & was	regular	presumptive
	dilated	discharged 30 days	intervals	COVID-19
	cardiomyopath	later.	beginning	pneumonitis &
	y with end-		shortly after	superimposed
	stage heart	Pt2: orthotopic heart	admission.	bacterial
	failure, type-2	transplant with		pneumonia;
	diabetes	antithymocyte	Pt 1: 5 days	day 21 O2
	mellitus,	globulin induction	post-discharge,	requirements
	hypothyroidism	therapy, discharged 4	rehospitalized	increased
	, osteoporosis,	weeks later.	following	significantly.
	and anemia.		community	Despite

Study ID	Participants (data extracted	Transplant,	Clinical course	COVID-19 treatments
	for transplant	treatment &	infection	
	patients)	comorbidities		
		Pt1 and Pt2:	exposure to	discontinuation
	Pt2: 33 yr F	prednisone,	COVID-19.	of MMF &
	with a history	tacrolimus, and	Nasal	reduction of
	of end-stage	mycophenolate	stuffiness &	tacrolimus,
	heart failure	mofetil, and standard	discharge,	cultivatable
	2ndary to	prophylactic	sneezing,	viral loads
	congenital	medications	fatigue &	increased in
	heart disease,		cough	the NP & saliva;
	liver cirrhosis &		developed on	chest
	kidney disease.		admission day	radiograph &
			4; NP swab +ve	clinical
			for SARS-CoV-	condition
			2. All	deteriorated;
			symptoms	mechanical
			except fatigue	ventilation
			resolved by	considered. 10-
			day 12.	day course of

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
	patients)	comorbidities	Dyspnea, cough & hypoxia then developed on day 15; chest radiograph revealed new bibasilar interstitial infiltrates. Discharged day 44. Pt2: tested +ve for SARS-CoV-2 shortly after discharge,	remdesivir initiated day 27. Clinical condition & chest radiograph improved; O2 discontinued day 32; discharged day 44. Pt2: intubation. MMF dose was reduced; dexamethason e &
			uischarge,	cα

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
			readmitted 1 week later with progressive dyspnea & hypoxemia requiring intubation. Significant viable virus burdens were noted in the NP swab (& saliva, & a used	antimicrobials initiated. MMF was subsequently held & later restarted when an echocardiogra m demonstrated a reduction in left ventricular systolic function, suggesting
			face cloth) 16 days after	acute graft rejection.

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
			initial SARS-CoV-2 positivity. 5-day course remdesivir initiated followed by clinical recovery & discharge 7 days later.	Pt1: 10-day course of remdesivir from day 27 to day 37 from hospital admission; improvement and subsequent discharge on day 44 Pt2: 5-day course remdesivir,

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
				improvement and discharge 7 days later
Tarhini 2021	71yr European M	Cardiac transplant, also diabetes mellitus & chronic kidney disease; prednisone, mycophenolic acid, belatacept	15 April 2020 hospitalized for asthenia, dry cough, myalgia, and low-grade fever for 1 week. No dyspnea or O2 need. +ve on admission and day 14 with <10% Covid-19	At readmission, treated in ICU for cardiac decompensatio n due to underlying respiratory infection. [Unclear what happened after this; last test day 121 & culture +ve at

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
			involvement	day 103,
			on CT scan.	negative
			Discharged day	serology
			39 after clinical	throughout]
			improvement,	
			despite	
			persistent +ve	
			PCR at day 32	
			(21 Ct). 23	
			June	
			readmitted	
			with dry	
			cough,	
			dyspnea, and	
			O2	
			requirement.	

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
Weigang 2021	58 yr M	kidney transplant, also CHD, arterial hypertension, hyperlipidemia, obesity; basiliximab (20mg, day 0 and day 4 post- transplantation) and prednisone (250mg at day 0, 125 mg day 1, 50mg day 2 to 5, 20mg day 6 to 10, then 15 mg/day). Additionally tacrolimus (10mg day	mild respiratory symptoms & tested positive for SARS-CoV-2 for over 145 days; discharged on day 72 for home quarantine; re- hospitalized at day 106 to 126 due to another kidney	lvermectin 4 day course (33mg/day, day) 56 to 60); 10 day course remdesivir (200 mg on day 140, then 100 mg/daily, day 141 to 149)
		0, 8mg day 1,	transplant	

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
		5.5mg day 2, 5mg day	failure. Days	
		3 and 4, then	140 to 149	
		4mg/day) and	treated with	
		Mycophenolate	remdesivir;	
		mofetil (2000mg/	subsequent	
		day). Maintenance	PCR tests	
		immunosuppression	negative &	
		consisted of	virus isolation	
		tacrolimus (4 to	negative.	
		6mg/day),		
		mycophenolate		
		mofetil		
		(2,000mg/day), and		
		prednisone (10 to		
		20mg/day)		

511 Abbreviations:

512 APS = anti-phospholipid syndrome

513	AZA = azathioprine
514	CAD = coronary artery disease
515	DM = diabetes mellitus
516	HTN = hypertension
517	MMF = mycophenolate mofetil
518	NP = nasopharyngeal
519	Pt = patient
520	RTI = respiratory tract infection
521	RT-PCR = reverse transcriptase polymerase chain reaction
522	

Table 2. Quality of included studies.

Study ID	Were the criteria for diagnosing a case clearly reported and appropriate ?	Was the reporting of patient/ population characteristic s adequate?	Was the study period, including follow-up, sufficient?	Were the methods used to obtain RT-PCR results replicable and appropriate?	Were the methods used to obtain viral culture results replicable and appropriate?
Alshukairi 2021	Unclear*	No**	Yes	Yes	Unclear
Aydillo 2020	Unclear	Yes	Yes	Unclear	Yes
Benotmane I 2021	Yes	Yes	Yes	Yes	No***
Decker A 2020	No	Yes	Yes	Unclear	Unclear
Lang C 2020	Yes	Yes	Yes	Unclear	Unclear
Niess 2020	Yes	Yes	Yes	Yes	Unclear
Niyonkuru M 2021	No*	Yes	Yes	Yes	Yes
Rajakumar 2021	Yes	Yes	Yes	Yes	Yes

Tarhini 2021	Yes	Yes	Yes	Yes	Yes
Weigang 2021	Yes	Yes	Yes	Yes	Yes

- *case definition unclear, article reports positive RT-PCR, but Ct cut-off not reported.
- ** data on clinical symptoms lacking

524

- ***The cell line used was not one that is demonstrated to support SARS-CoV-2 growth.
- 528 Therefore the cell culture results are not reliable.

Table 3. PCR cycle counts/log copies and viral culture results of included studies.

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
Alshukairi	NR no viral	Pt1: D3: positive, Ct NA, D26:	Pt1: D26: negative
2021	culture at	positive, 22.87	Pt2: D17: negative
	admission/ons	Pt2: D3: positive, 11.58; D17:	Pt3: D19: negative
	et of	positive, 23.12	Pt4: D12: negative
	symptoms	Pt3: D6: positive, 8.82, D19:	Pt5: D9: negative
		positive, 13.88	
		Pt4: D4: positive, 10.38; D12:	
		positive, 27.57	
		Pt5: D1: positive, 2.8, D9:	
		positive, 14.84	
Aydillo 2020	All	Pt1: D3: 22.5, D27: 34	Pt1 D3: positive, D27: negative
*	symptomatic;	Pt2: D2: 18, D27: 32	Pt2: D2: positive, D27, negative
	variable	Pt4: D5: 19, D28: 18.5, D50: 27.5	Pt4: D5: positive, D28: positive,
	severity		D50: negative
		Pt6: D18: 21, D27: 21.5, D33:	Pt6: D18: negative, D27:
		30.5, D38: 20, D45: 19.5, D52:	negative, D33: negative, D38:

Study ID	Symptoms,	RT-PCR Cycle count/log copies	Viral culture results (days)
	days reported	results	
		20, D62: 18.5	negative, D45: positive, D52:
			positive, D62: positive
		Pt8: D1: 22, D17: 21, D22: 22,	Pt8: D1: positive, D17:
		D37: 35	positive, D22: negative, D37:
			negative
		Pt9: D4: 13, D8: 22, D46: 33.5,	Pt9: D4: positive, D8: positive,
		D56: 27, D82: 38	D46: negative, D56: negative,
			D82: negative
		Pt13: D2: 21.5, D50: 31.5	Pt13: D2: positive, D50:
			negative
		Pt14: D8: 17.5	Pt14: D8: positive
Benotmane			Pt1: D5, D14: negative;
2021			Pt2: D21, D29: negative;
			Pt3: D25, D39: negative
			Pt4: D2: positive, D9, D16, D35:
			negative
		Patient 6: D23: Ct > 30; D29: Ct >	Pt5: D1, D8: positive; D23, D30:
		35	negative

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
		Patient 7: D38: Ct > 35	Pt6: D6, D9, D23, D29: positive
		Patient 8: D28: Ct > 30	Pt7: D7, D38: positive
			Pt8: D1: negative, D8, D28:
			positive
		Patient 11: D27: Ct > 30	Pt9: D11: negative, D30:
			negative
			Pt10: D2, D8: negative
			Pt11: D11, D27: positive
			Pt12: D17, D27: negative
			Pt13: D2, D9: positive; D31:
			negative
			Pt14: D3, D19: negative
			Pt15: D4, D17: negative
			Pt16: D20: positive, D30:
			negative.
Decker 2020	Mild	PCR +ve on days 1, 5, 7, 11, 18,	Viral culture +ve at day 18 and
	symptoms. Day	21, 25, 28, 33, and still on day 35	day 21 post-onset of
	0: transient	PCR remained positive on day 35	symptoms.

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
	episode of fever & sore throat; day 7 temperature increase; no clinical symptoms	with copy numbers similar to the onset of infection. Concurrent with the second onset of fever there was an increased viral load after day 7 that slowly returned to the level of infection onset.	
	after day 20.		
Lang 2020	Admitted with fever & cough becoming severe and life threatening leading to bilateral lung transplant.	Day 0, Ct 27; Day 17, Ct 21; Day 23, Ct 23; Day 19, Ct 32; Day 31, Ct 32; Day 36, Ct 29; Day 48, Ct 39; Day 53, Ct 34; Day 59, Ct 33; Day 61, PCR negative; Day 62, Ct 36; Day 62, PCR negative; Day 64, PCR negative; Day 65, Ct 36; Day 66, Ct 39; Day 69, Ct 39; Day 70, PCR negative; Day 72, PCR negative; Day 74, PCR negative;	Samples cultured from day 48 and day 65; both negative by cell culture.

Study ID	Symptoms,	RT-PCR Cycle count/log copies	Viral culture results (days)
	days reported	results	
		Day 76, PCR negative; Day 95,	
		PCR negative;	
Niess 2020	Mild	day 0: positive but	Positive pre-transplant PCRs
	symptoms of	asymptomatic	were not confirmed by cell
	malaise and a	day 8, 12, 19, 22 - positive PCR	cultures
	dry cough	day 31, 32 - negative PCR	
		day 49, 55, 60 - positive PCR	4 negative viral cell culture
		day 58, 63, 64 - negative PCR	results from samples taken on
		results	days 49, 54, 60 and 69
			(*)
Niyonkuru	Pt1: fatigue	Pt1: day 15 from 1st positive	Pt1: day 15 from 1st positive
2021	and tachypnea,	PCR/day 3 from symptoms	PCR/day 3 from
	then	onset: Cq 21.7; day 21 from 1st	symptoms onset viral culture
	ventilation	positive PCR/day 9 from	at 61,277 PFU/swab; day 21
	required.	symptoms onset: Cq 19.21; day	from 1st positive PCR/day 9
		43 from 1st positive PCR/day 13	from symptoms onset viral
	Pt2:	from symptoms onset Cq 35.45	culture at 256,410 PFU/swab;

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
	asymptomatic		day 22 from 1st positive
	for COVID-19.	Pt2: day 9 from 1st positive PCR:	PCR/day 13 from symptoms
		Cq: 22.33; day 12 from 1st	onset viral culture negative.
		positive PCR Cq 22.57; day 14	
		from 1st positive PCR: Ct approx	Pt2: day 9 from 1st positive
		33.5; day 18 from 1st positive	PCR: culture positive with
		PCR: PCR negative.	11082 PFU/swab; day 12 from
			1st positive PCR: culture
			positive with PFU 55944/swab;
			day 14 from 1st positive PCR:
			culture negative.
Rajakumar		Pt 1: hospital admission, positive	Pt1
2021		PCR day 4 post-symptom onset	Viral culture
		Day 4: N gene Ct 16, E gene Ct	Day 4: positive
		19	Day 12: positive
		Day 12: N gene Ct 13, E gene Ct	Day 20: positive
		20	Day 27: positive

Study ID	Symptoms,	RT-PCR Cycle count/log copies	Viral culture results (days)
	days reported	results	
		Day 20: N gene Ct 14, E gene Ct	Day 32: negative
		19	Day 60: negative
		Day 27: N gene Ct 15, E gene Ct	
		21	Pt 2: Viral culture
		Day 32: N gene Ct 32, E gene Ct	Day 16: positive
		28	Day 22: negative
		Day 60: N gene Ct 30, E gene Ct	Day 25: negative
		35	Day 42: negative
			Day 51: negative
		Pt 2:	
		Day 16: N gene Ct 14, E gene Ct	
		20	
		Day 22: N gene Ct 25, E gene Ct	
		33	
		Day 25: N gene Ct 25, E gene 29	
		Day 42: N gene Ct 29, E gene Ct	
		37	
		Day 51: N gene Ct 37, E gene Ct	
		39	

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
Tarhini 2021	Severe	Day 6: Ct=25,	Day 6: culture negative
	infection	Day 16: Ct=24	Day 16: culture negative
	requiring	Day 32: Ct=20	Day 80: culture negative
	intensive care	Day 78: Ct=34	Day 91: culture negative
		Day 80: Ct=24	Day 103: culture positive
		Day 91: Ct=28	Day 111: culture negative
		Day 103: Ct=23	Day 120: culture negative
		Day 109: Ct=18	
		Day 120: Ct=26	(*)
		Day 132: Ct=40+ (negative)	
		Day 136: Ct=40+ (negative)	
		(*)	
Weigang	Mild	38 PCR tests: days 0, 6, 10, 14,	27 cell culture tests, days: 0, 6,
2021	respiratory	16, 21, 24, 27, 31, 34, 38, 42, 45,	10, 14, 16, 21, 24, 27, 31, 34,
	symptoms for	46, 49, 52, 56, 58, 63, 65, 71,	38, 42, 45, 49, 52, 56, 58, 63,
	over 145 days	105, 113, 115, 119, 122, 126,	65, 71, 105, 106, 113, 115, 119,
		140, 143, 145, 146, 149, 150,	140, 154; 27 results: -, +, +, +, -,

ys reported	results	
	154, 161, 167, 174, 189. 38	+, +, +,+, +, -, -, -, -, -, -, -, -, -, +,
		-, -, -, -, -, (i.e. positive on
	Ct values: 25, 16, 19, 19, 25, 23,	days 6, 10, 14, 21, 24, 27, 31,
	18, 26, 20, 17, 31, 27, 27, 50, 27,	34, 105)
	28, 25, 28, 27, 29, 30, 23, 34, 29,	
	31, 31, 36, 26, 29, 34, 39, 45, 45,	
	34, 45, 45, 45, 45.	
		Ct values: 25, 16, 19, 19, 25, 23, 18, 26, 20, 17, 31, 27, 27, 50, 27, 28, 25, 28, 27, 29, 30, 23, 34, 29, 31, 31, 36, 26, 29, 34, 39, 45, 45,

- (*) Numbers have been read from a figure in the published article and may not be an accurate
- 534 estimate.

531

532

- 536 Ct = cycle threshold
- 537 D = day
- 538 NR = not reported
- 539 NA = not available
- 540 Pt = patient
- RT-PCR = reverse transcriptase polymerase chain reaction

Figure 1. PRISMA flow chart of study screening for inclusion.




Figure 2. SARS-CoV-2 culture results in transplant patients from days of symptom onset.

SARs-CoV-2 culture results in transplant patients from days of symptom onset

120

80

80

Culture Positive (n=59)

Culture Negative (n=107)

Culture positive (n=59 samples): median 16 (IQR 8-27, Range 1-105 days, mean 19.7 days Culture negative (n=107 samples): median 40 (IQR 22-60), Range 1-119 days, mean 43.2 days

Figure 3a. Timings of positive culture results in Transplant Patients by duration of symptoms and Ct results Alshukairi [7], Benotmane [8], Rajakumar [15] & Niyonkuru [14] (days 1- 42)




Figure 3b. Timings of positive culture results in Transplant Patients by duration of symptoms and Ct results Aydillo ^[6] (day 1-90), Tarhini ^[9] & Weigang ^[12] (day 1-120)



Negative Culture
Positive Culture
Number equals RT-PCR Cycle Threshold

Figure 3c. Timings of positive culture results in Transplant Patients by duration of symptoms and log10 copies/ml results Decker ^[10] (days 1-36)

Decker 2020 log10 copies/ml, 1 4.5 4 6 6.2 6.5 5 4.5 4 4 > 4 log10 decemed eve 5 4.5 4 4
A logo decined ive

